Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922941 | 0.78 | MEN1 (0.51) | MAPTKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL25291704 | 0.78 | RAB9A (0.36) | MAPTKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL921882 | 0.77 | MEN1 (0.46) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL26122031 | 0.75 | REV1 (0.33) | — | |
| SCHEMBL924008 | 0.71 | L3MBTL1 (0.38) | MAPTMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL922994 | 0.70 | DEPTOR (0.32) | BACE1KMT2ASMN1; SMN2HTT | |
| SCHEMBL922392 | 0.70 | ALDH1A1 (0.32) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL476469 | 0.69 | — | — | |
| SCHEMBL26120351 | 0.69 | NPC1 (0.43) | MAPTMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL26122563 | 0.69 | GAA (0.48) | MAPTKDM4EMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321043-A1 | COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES | UNIV COPENHAGEN (DK) | 2023-10-12 | — | — | US | disclosed |
| US-20230321043-A1 | COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES | UNIV COPENHAGEN (DK) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321043-A1 | COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES | GMPS, PDE11A, CGAS | NAPRT 1686/4885BACE1 3952/4885GSK3A 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.